Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 4, 2021 Expiration: October 3, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca
Nicoletta Colombo, MD
person default
Philipp Harter, MD, PhD
person default
Alexandra Leary, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate available long-term follow-up data from clinical trials investigating the use of PARP inhibitors in the management of ovarian cancer
  • Plan PARP inhibitor–based therapeutic strategies for patients with ovarian cancer based on available data, long-term clinical experience, expert recommendations, and patient preferences
  • Identify patients with ovarian cancer most likely to benefit from PARP inhibitor therapy as single agents or in combination
  • Compare and contrast the toxicities associated with PARP inhibitors commonly used in therapy for ovarian cancer, and understand the available supportive management strategies
  • Discuss with patients and colleagues ongoing clinical studies of PARP inhibitor–based treatment in ovarian cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Nicoletta Colombo, MD

Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Nicoletta Colombo, MD, has disclosed that she has received consulting fees from AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GlaxoSmithKline, ImmunoGen, Mersana, MSD/Merck, Novartis, Pfizer, Pharmamar, Roche, Takeda, and Tesaro.
Philipp Harter, MD, PhD

Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany

Philipp Harter, MD, PhD, has disclosed that he has received funds for research support from AstraZeneca, Clovis, Genmab, GlaxoSmithKline, ImmunoGen, MSD/Merck, and Roche and consulting fees from AstraZeneca, Clovis, GlaxoSmithKline, ImmunoGen, MSD/Merck, Roche, and Stryker/Zailab.
Alexandra Leary, MD, PhD

Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from Ability, AstraZeneca, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme, and Tesaro and consulting fees from Ability, AstraZeneca, BIOCAD, Clovis Oncology, GlaxoSmithKline, Merck Serono, Merck Sharp & Dohme, Seattle Genetics, Tesaro, and Zentalis.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for global gynecologic oncologists, medical oncologists, and other healthcare professionals who care for patients with ovarian cancer.

Goal

The goal of this activity is to educate global gynecologic oncologists, medical oncologists, nurses, and other healthcare professionals about the recent developments in the use of PARP inhibitors in the treatment of ovarian cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 04, 2021, through October 03, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy
  • CME

Loading...
Watch this on-demand webcast capturing a live CCO webinar during IGCS 2021 of experts discussing the evolving strategies and expanding role of PARP inhibitors in managing patients with ovarian cancer.
Nicoletta Colombo, MD
person default
Philipp Harter, MD, PhD
person default
Alexandra Leary, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 4, 2021 Expiration: October 3, 2022

Related Content

Podcast episode with expert insights on important trial data for ovarian and endometrial cancers from the ESGO 2021 annual meeting, from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: November 23, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Nicole Concin, MD, PhD Bernard Doger de Spéville, MD, PhD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Prof Isabelle Ray-Coquard, MD, PhD Released: November 15, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue